BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28392461)

  • 1. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy.
    Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS
    Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
    Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
    Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.
    Liu WJ; Zhu KL; Xu J; Wang JL; Zhu H
    Lab Invest; 2018 Dec; 98(12):1538-1548. PubMed ID: 30206309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
    Qin Y; Liu XJ; Li L; Liu XJ; Li Y; Gao RJ; Shao RG; Zhen YS
    Oncol Rep; 2014 Jul; 32(1):121-30. PubMed ID: 24807584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
    Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
    PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.
    Liu WJ; Liu XJ; Xu J; Li L; Li Y; Zhang SH; Wang JL; Miao QF; Zhen YS
    Acta Pharmacol Sin; 2018 Nov; 39(11):1777-1786. PubMed ID: 30013033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein.
    Cai L; Chen H; Miao Q; Wu S; Shang Y; Zhen Y
    J Biotechnol; 2009 Oct; 144(2):142-50. PubMed ID: 19737585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
    Guo XF; Zhong GS; Miao QF; Zhen YS
    Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation.
    Liu WJ; Liu XJ; Li L; Li Y; Zhang SH; Zhen YS
    Cancer Immunol Immunother; 2014 Dec; 63(12):1261-72. PubMed ID: 25164878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
    Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS
    Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
    Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
    Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
    Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
    Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.
    Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y
    Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.